X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The Company’s clinical study is evaluating the safety and feasibility of oral psilocybin as a potential treatment for methamphetamine use disorder conducted under an investigator-initiated IND.
Lead Product(s): Psilocybine
Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 02, 2024
Details:
Bucillamine is an oral potent thiol donor small molecule drug, which is being evaluated in phase 3 clinical trials for the treatment of Covid-19 infection.
Lead Product(s): Bucillamine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 27, 2024
Details:
Bucillamine is an oral potent thiol donor small molecule drug, which is being evaluated in phase 3 clinical trials for the treatment of Covid-19 infection.
Lead Product(s): Bucillamine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 19, 2024
Details:
The company intends to use the net proceeds of the offering for clinical development of Bucillamine, which is an antirheumatic agent developed from tiopronin for the treatment of long-term COVID-19.
Lead Product(s): Bucillamine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Hampton Securities Limited
Deal Size: $2.1 million Upfront Cash: Undisclosed
Deal Type: Private Placement February 26, 2024
Details:
The net proceeds will be used for the clinical development of a bucillamine, which is a thiol-based drug with anti-inflammatory and antiviral properties a potential treatment for long-term COVID disease.
Lead Product(s): Bucillamine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Canaccord Genuity Corp
Deal Size: $0.9 million Upfront Cash: Undisclosed
Deal Type: Private Placement January 31, 2024
Details:
The company intends to use the net proceeds to advance bucillamine, a small molecule prescribed in the treatment of rheumatoid arthritis in Japan and South Korea, for clinical work on long COVID and other possible indications.
Lead Product(s): Bucillamine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $3.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement January 24, 2024
Details:
Bucillamine is a potent antioxidant and anti-inflammatory, small molecule drug candidate. It is being evaluated for the treatment of nerve agent induced brain injury seizure.
Lead Product(s): Bucillamine,Acetylcysteine
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 16, 2024
Details:
Bucillamine is an oral potent thiol donor small molecule drug, which is being evaluated in phase 3 clinical trials for the treatment of Covid-19 infection.
Lead Product(s): Bucillamine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 10, 2024
Details:
The collaboration aims for the clinical and commercial development of Revive’s lyophilized formulation of Bucillamine, a potent antioxidant and anti-inflammatory and may be helpful for orphan indications in rare inflammatory disorders such as ischemia-reperfusion injury.
Lead Product(s): Bucillamine
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: Undisclosed
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Attwill Medical Solutions
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration December 18, 2023
Details:
The agreement aims to evaluate Bucillamine, a significantly more effective antioxidant than n-acetylcysteine, as a potential treatment for nerve agent exposure.
Lead Product(s): Bucillamine
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Defence R&D Canada
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement October 17, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
